Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
about
Other targeted drugs in melanomaCancer stem cell targeted therapy: progress amid controversies.Mammary gland stem cells and their application in breast cancerComparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.E3 Ubiquitin Ligases Neurobiological Mechanisms: Development to DegenerationApoptotic death of cancer stem cells for cancer therapy.A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancerNew targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancersTime-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors.Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical updateTargeting the Notch pathway: A potential therapeutic approach for desmoid tumorsNUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer.Targeting notch signaling pathway in cancer: clinical development advances and challengesPhase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.Concise reviews: cancer stem cells: from concept to cure.Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancerBreast cancer stem cells: are we ready to go from bench to bedside?Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells.Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy.Prognostic significance of ABCB1 in stage I lung adenocarcinoma.GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation.Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.Epithelial-mesenchymal transition - activating transcription factors - multifunctional regulators in cancer.[(3) H]-L685,458 binding sites are abundant in multiple peripheral organs in rats: implications for safety assessment of putative γ-secretase targeting drugs.Targeting Stemness: Implications for Precision Medicine in Breast Cancer.Crosstalk between Notch, HIF-1α and GPER in Breast Cancer EMTSynergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinomaSynergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells
P2860
Q26775594-0E46F30D-64FB-4D72-95E1-80A155A8A662Q26779931-07EE65F4-E7EF-4876-BEE6-D80069EE24D7Q28075791-7B2879AB-6A96-4148-9311-616D030007F5Q30434130-25EA98F4-D7AB-4B5E-8E28-67FB6A56F0A3Q33705444-360E336E-1817-4DD8-94BA-7B80194CDEC0Q33755766-A14C80CE-9831-4B08-9AED-B99BA8FF8735Q34499662-BB79DCD4-5563-4F59-A0B0-8F5F6E7E082AQ34591131-B28ACBEB-BFEF-4E5D-BBAF-57E6CD1A8A6BQ34706060-A36764FF-E624-4A1B-9371-E3DFE648C050Q35582077-0EF27C23-A125-472A-B5E8-9526BEDD3E9CQ35904255-E9BF0F13-28C0-418C-8C71-393CFE30D9C4Q35904534-DB7345A0-D585-4CED-A656-E4792BEA5D7CQ36253804-A99270F6-9BF8-45A9-B07D-7A8177BD4A41Q37589507-EAA30CDC-D134-4F66-A380-4EC11C463961Q37696748-09D34F2F-F098-4DE6-91F5-07C9EFC32CA8Q37709275-500A01AC-DE51-4575-B8A8-5CE58FC845E4Q38235552-A2AA8BBA-0237-4210-92BB-D8751D4A53F1Q38267262-AF551552-2A00-43C2-A953-03A4D93EA51BQ38696803-F256D09C-8BB6-4878-B4A6-4E1C0FC2B92BQ38753118-280E419D-833C-46EA-A7D8-E5D5F9BC87D1Q38850154-78685119-EEF5-45B0-9783-E9BB033863CBQ38952558-5F02A11C-A741-4FD0-BA63-7AF859A321BAQ40978136-E4B70580-0F57-4F31-8558-DD3C05D8D16BQ41958214-E4A802BD-F43F-4941-BB76-AFF23D8E301BQ42700663-473C2F1B-736E-4476-BF55-934DCDDD0A2FQ42928789-FA363AE8-FA92-45C4-94EE-40AB2BE1BCDDQ48767057-B9CC6592-ABAA-4E25-8C6A-C8E1C699E462Q49544368-F8590D08-7A05-4896-A729-746DA700D22AQ57109688-D5C721F8-140B-4E95-80EC-2EF185195AB1Q58579029-191DA25B-C78C-4E39-9286-4465FC0BFBF6Q59125598-B2F4E56F-311A-40F0-98C0-97DED33D1BC1
P2860
Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Synergistic effect of the γ-se ...... taxel in breast cancer models.
@en
type
label
Synergistic effect of the γ-se ...... taxel in breast cancer models.
@en
prefLabel
Synergistic effect of the γ-se ...... taxel in breast cancer models.
@en
P2093
P2860
P356
P1476
Synergistic effect of the γ-se ...... taxel in breast cancer models.
@en
P2093
Annette John-Baptiste
Cathy C Zhang
Cory Painter
Douglas D Fang
Enhong Chen
James G Christensen
Maruja E Lira
Zhengming Yan
P2860
P304
P356
10.5966/SCTM.2012-0096
P577
2013-02-13T00:00:00Z